about
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaSafety of available treatment options for renal cell carcinoma.Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Axitinib in metastatic renal cell carcinoma.
@en
type
label
Axitinib in metastatic renal cell carcinoma.
@en
prefLabel
Axitinib in metastatic renal cell carcinoma.
@en
P2093
P2860
P1476
Axitinib in metastatic renal cell carcinoma.
@en
P2093
Edith Carton
Laurence Albiges
Marco Gizzi
P2860
P304
P356
10.1586/14737140.2015.1033408
P577
2015-05-01T00:00:00Z